0.88
-0.0463(-5.00%)
Currency In USD
| Previous Close | 0.93 |
| Open | 0.9 |
| Day High | 0.92 |
| Day Low | 0.85 |
| 52-Week High | 5.95 |
| 52-Week Low | 0.81 |
| Volume | 214,452 |
| Average Volume | 2.03M |
| Market Cap | 9.5M |
| PE | -0.65 |
| EPS | -1.35 |
| Moving Average 50 Days | 1.13 |
| Moving Average 200 Days | 1.62 |
| Change | -0.05 |
If you invested $1000 in Marker Therapeutics, Inc. (MRKR) 10 years ago, it would be worth $11.83 as of September 30, 2025 at a share price of $0.88. Whereas If you bought $1000 worth of Marker Therapeutics, Inc. (MRKR) shares 5 years ago, it would be worth $58.67 as of September 30, 2025 at a share price of $0.88.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Aug 28, 2025 12:00 PM GMT
HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and so
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
GlobeNewswire Inc.
Aug 26, 2025 11:00 AM GMT
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating complete response (CR) Favorable safety profile o
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire Inc.
Jul 30, 2025 12:00 PM GMT
HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and so